Baidu
map

国际癌症研究机构:注意了!50岁以下人群结直肠癌发病率正在升高!

2021-08-14 MedSci原创 MedSci原创

结直肠癌(CRC)是一种常见的致命疾病。

结直肠癌(CRC)是一种常见的致命疾病。筛查能提供获益,因为切除早期腺瘤可以预防CRC,切除局限性癌症或许能预防CRC相关性死亡。CRC在40岁前并不常见;40岁后,发病率逐渐上升,到80岁时达到每年3.7/1000。美国一般风险患者的CRC终生发病率为4.5%,其中90%的病例发生在50岁以后。

在世界范围内,CRC是女性中第二常见、男性中第三常见的癌症,在2012年造成了69多万例死亡。在美国,CRC是癌症死亡的第二大病因,CRC引起的死亡约占总体癌症死亡的8.4%。大约每3例CRC患者中有1例会因此死亡。

有一个令人欣慰的现象便是,最近几年来,大家普遍认识到筛查是预防CRC一个十分重要的措施。在2004-2013年间,CRC的死亡率平均每年下降2.7%。微观模拟模型MISCAN-Colon提示,所观察到的CRC死亡率下降,可能约有53%得益于CRC筛查。一项有关美国CRC发病率和筛查率的时间趋势的研究报道,从1987-2010年,约25-50万例CRC病例可能通过筛查得到了预防,同时发现的CRC由晚期向早期疾病转变。

目前,欧洲各国的结直肠癌筛查方案和接受情况有很大的不同。在许多高收入国家,结肠直肠癌的总体发病率正在下降,然而在美国和其他高收入国家,如澳大利亚、加拿大和挪威的分析表明,50岁以下的成年人的发病率正在上升。

那么不同国家大肠癌发病率、死亡率和分期分布随时间的变化如何呢?为了讨论上述问题,国际癌症研究机构对7个发达国家进行了跨国研究,结果发表在Lancet Gastroenterology & Hepatology杂志上。

研究人员从澳大利亚、加拿大、丹麦、挪威、新西兰、爱尔兰和英国的20个以人口为基础的癌症登记处获得了结肠癌和直肠癌的发病率数据,使用年龄-时期-队列模型来评估各年龄组、时期和出生队列的发病率趋势。

7个国家不同年龄段年龄标准化的发病率

所有研究国家都注意到结肠癌和直肠癌发病率的总体下降或稳定。然而,在有数据可查的最近10年期间,丹麦(每年3.1%)、新西兰(每年2.9%)、澳大利亚(每年2.9%)和英国(每年1.8%)50岁以下人群的结肠癌发病率显著上升。在加拿大(每年3.4%)、澳大利亚(每年2.6%)和英国(每年1.4%),这一年龄组的直肠癌发病率的年平均百分比变化也有明显的增加。

同时,在50-74岁的人群中,结肠癌发病率的年平均百分比变化在澳大利亚(每年1.6%)、加拿大(每年1.9%)和新西兰(每年3.4%)显著下降,直肠癌的发病率在澳大利亚(每年2.4%)、加拿大(每年1.2%)和英国(每年1.2%)显著下降。

7个国家50岁以下年龄段年龄标准化的发病率

此外,50岁以下人群结直肠癌发病率的增加主要是由结肠远端(左侧)肿瘤的增加引起的。在所有国家,使用非线性队列效应,直肠癌比结肠癌更明显。

综上,本研究7个国家中50岁以下人群的结直肠癌发病率大幅增加。

 

参考文献:

Changes in colorectal cancer incidence in seven high-income countries: a population-based study. DOI:https://doi.org/10.1016/S2468-1253(19)30147-5

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1823738, encodeId=677e1823e3887, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Fri Apr 08 19:12:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935397, encodeId=3bf5193539e25, content=<a href='/topic/show?id=44dce341015' target=_blank style='color:#2F92EE;'>#研究机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73410, encryptionId=44dce341015, topicName=研究机构)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Feb 07 11:12:45 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799906, encodeId=cbe81e99906be, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Dec 06 01:12:45 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079299, encodeId=2f4a20e929903, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Apr 01 03:12:45 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453559, encodeId=e5c51453559a7, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Aug 16 08:12:45 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514209, encodeId=995715142097b, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Aug 16 08:12:45 CST 2021, time=2021-08-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1823738, encodeId=677e1823e3887, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Fri Apr 08 19:12:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935397, encodeId=3bf5193539e25, content=<a href='/topic/show?id=44dce341015' target=_blank style='color:#2F92EE;'>#研究机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73410, encryptionId=44dce341015, topicName=研究机构)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Feb 07 11:12:45 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799906, encodeId=cbe81e99906be, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Dec 06 01:12:45 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079299, encodeId=2f4a20e929903, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Apr 01 03:12:45 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453559, encodeId=e5c51453559a7, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Aug 16 08:12:45 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514209, encodeId=995715142097b, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Aug 16 08:12:45 CST 2021, time=2021-08-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1823738, encodeId=677e1823e3887, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Fri Apr 08 19:12:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935397, encodeId=3bf5193539e25, content=<a href='/topic/show?id=44dce341015' target=_blank style='color:#2F92EE;'>#研究机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73410, encryptionId=44dce341015, topicName=研究机构)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Feb 07 11:12:45 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799906, encodeId=cbe81e99906be, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Dec 06 01:12:45 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079299, encodeId=2f4a20e929903, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Apr 01 03:12:45 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453559, encodeId=e5c51453559a7, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Aug 16 08:12:45 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514209, encodeId=995715142097b, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Aug 16 08:12:45 CST 2021, time=2021-08-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1823738, encodeId=677e1823e3887, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Fri Apr 08 19:12:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935397, encodeId=3bf5193539e25, content=<a href='/topic/show?id=44dce341015' target=_blank style='color:#2F92EE;'>#研究机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73410, encryptionId=44dce341015, topicName=研究机构)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Feb 07 11:12:45 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799906, encodeId=cbe81e99906be, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Dec 06 01:12:45 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079299, encodeId=2f4a20e929903, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Apr 01 03:12:45 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453559, encodeId=e5c51453559a7, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Aug 16 08:12:45 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514209, encodeId=995715142097b, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Aug 16 08:12:45 CST 2021, time=2021-08-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1823738, encodeId=677e1823e3887, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Fri Apr 08 19:12:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935397, encodeId=3bf5193539e25, content=<a href='/topic/show?id=44dce341015' target=_blank style='color:#2F92EE;'>#研究机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73410, encryptionId=44dce341015, topicName=研究机构)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Feb 07 11:12:45 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799906, encodeId=cbe81e99906be, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Dec 06 01:12:45 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079299, encodeId=2f4a20e929903, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Apr 01 03:12:45 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453559, encodeId=e5c51453559a7, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Aug 16 08:12:45 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514209, encodeId=995715142097b, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Aug 16 08:12:45 CST 2021, time=2021-08-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1823738, encodeId=677e1823e3887, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Fri Apr 08 19:12:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1935397, encodeId=3bf5193539e25, content=<a href='/topic/show?id=44dce341015' target=_blank style='color:#2F92EE;'>#研究机构#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73410, encryptionId=44dce341015, topicName=研究机构)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Mon Feb 07 11:12:45 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1799906, encodeId=cbe81e99906be, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Mon Dec 06 01:12:45 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079299, encodeId=2f4a20e929903, content=<a href='/topic/show?id=659ce1280ee' target=_blank style='color:#2F92EE;'>#癌发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71280, encryptionId=659ce1280ee, topicName=癌发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Fri Apr 01 03:12:45 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453559, encodeId=e5c51453559a7, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Aug 16 08:12:45 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514209, encodeId=995715142097b, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Aug 16 08:12:45 CST 2021, time=2021-08-16, status=1, ipAttribution=)]

相关资讯

Endoscopy:结肠镜检查的质量和并发症发生率

治疗性和FIT阳性筛查结肠镜检查的穿孔率和出血率最高

Cancer Commun:免疫检查点抑制剂治疗结直肠癌的疗效和毒性:真实世界研究

跟临床研究一样,相对于pMMR/MSI-L/MSS CRC患者,ICB对于dMMR /MSI-H更有效。早期使用ICB效果更好,特别是在pMMR/MSI-L/MSS CRC患者中。

Ann Intern Med:如何通过粪便更精准的筛查结直肠癌?

与FIT相比,mtFIT在检测高级别赘生物方面表现出了更好的诊断准确性

BMC Med:维生素D是怎么做到抗肿瘤的?与转录组变化有关!

较高的血浆25-OHD与直肠粘膜基因表达模式相关,与抗肿瘤作用一致,而且这种有益的特征是由短期维生素D补充剂引起的。

Cancers:水溶性SIGLEC5 (sSIGLEC5):结直肠癌的新预后指标

该研究表明,水溶性SIGLEC5 (sSIGLEC5)是结直肠癌患者的预后指标。

拓展阅读

读书报告 | 个性化新抗原特异性TCR转导T细胞在转移性结直肠癌中的II期试验的中期结果

本研究的早期结果表明,对于转移性结直肠癌患者采用基因修饰以表达个性化新抗原反应性TCRs的T细胞进行ACT是可以耐受的,并且可以介导肿瘤消退。

研究证实:喝咖啡,或能降低肠癌发病率!

《国际癌症杂志》(IJC)上刊登的一项研究,为我们揭示了咖啡与结直肠癌之间令人惊叹的关联。

IVD前沿:代谢组学在结直肠癌风险评估或早期检测中的潜力

本系统综述的目的是评估诊断前样本中CRC或其前体代谢物生物标志物的现有证据。

对话大咖 | 精准医疗的曙光:孙永琨教授解读结直肠癌靶向药物与联合治疗

【医悦汇】对话大咖栏目特别邀请中国医学科学院肿瘤医院孙永琨教授,为我们深入解读结直肠癌治疗的最新进展,探讨临床联合治疗策略的潜力及其未来的发展方向。

中山大学STTT:突破性进展!SHR-1701组合治疗显著提升晚期结直肠癌患者生存希望

中山大学骆卉妍、徐瑞华和邱妙珍等人评估了SHR-1701与贝伐珠单抗和XELOX化疗联合使用作为不可切除mCRC的一线治疗的疗效和安全性。

【论著】| KCMF1促进结直肠癌细胞增殖和NF-κB信号转导的机制研究

KCMF1在人CRC组织中呈高表达,并与患者的高临床分期和不良预后呈正相关;KCMF1可能通过激活NF-κB信号通路促进CRC细胞增殖。KCMF1可能是CRC的一个潜在治疗新靶点。

Baidu
map
Baidu
map
Baidu
map